508.460.8822 Contact Us

Measurement of drug in small particles from aqueous nasal sprays by Andersen Cascade Impactor

Pharm Res. 2012 Nov;29(11):3122-30. doi: 10.1007/s11095-012-0804-7. Epub 2012 Jul 3.

Doub WH1, Adams WP, Wokovich AM, Black JC, Shen M, Buhse LF.

Corresponding author:  william.doub@fda.hhs.gov

1Division of Pharmaceutical Analysis, Food and Drug Administration CDER, OPS, St. Louis, Missouri, USA.

ABSTRACT

PURPOSE: To determine if cascade impactor (CI) measurement of drug in small particles from aqueous nasal sprays, described in FDA’s 2003 draft Nasal Bioavailability/Bioequivalence Guidance, can be optimized to reduce measurement variability. To examine the influence of flow rate configurations and number of impactor stages on CI deposition and explore the importance of inlet volume.

METHODS:  A total of eight assemblies and manual vs. automatic actuation were tested for deposition on the sum of all stages of the CI, and for Group 2 total drug mass per the Guidance. Mean deposition and variance about the mean were determined for each assembly.

RESULTS:  The path length for a spherical 1 l inlet was too short to allow adequate aerosol formation. Data variance was reduced by a factor of two or more by using an automatic actuator relative to manual actuation. Impactor assembly modification did not improve variance over the standard assembly.

CONCLUSIONS:  Use of a spherical inlet (≥ 2 l volume) and automatic actuation are recommended for comparative measurements of drug in small particles arising from aqueous nasal sprays. The standard (8-stage) 28.3 lpm CI flow rate configuration is recommended when using the Andersen Cascade Impactor (ACI), as no other assembly showed a distinct advantage.

PMID: 22752252  [PubMed – indexed for MEDLINE]

Filter publications by

 
"Proveris Scientific Corporation provides expert support for nasal developers. They are fast, reliable and are professionals at installing of their equipment and supports in demanding challenges." Dr. Peter Svete, Head of Physical Analytics, Lek Pharmaceuticals d.d.
 
 
"Proveris provides insightful and thorough test services. We would recommend working with Proveris. Proveris has great expertise in spray analysis." Elaine Schutte, Chief Development Officer, ProFibrix
 
 
"I want to express my sincere gratitude towards Proveris and the service team for being there to make sure our study goes well. The study just completed few minutes ago and thankfully everything went well.......while we conducted SAC study. It was a great display of professionalism by Proveris." ,
 
 
"As customary, Proveris's service team provided excellent service and was able to answer my questions." ,
 
 
"Thank you for the thorough training on our new equipment. I wish more companies would implement your hands on approach when it comes to training. Thanks again." ,
 
 
“We really appreciate the creativity and work conducted at Proveris for their Test Services (Proveris by Design®). Their knowledge, experience, and insight with OINDP’s was very helpful. Thanks to the Proveris team, we have a wonderful solution that we can use for commercial products!” Mic Iwashima, NDS Division, Shin Nippon Biomedical Laboratories, Ltd